ClearPoint Neuro (CLPT) Gets FDA's Nod for SmartFrame OR System

ClearPoint Neuro, Inc. (CLPT) recently announced its receipt of the FDA’s 510(k) clearance for its SmartFrame OR Stereotactic System. The system is expected to offer flexible workflows to surgeons (including iCT forward projection), thereby enabling precise image-based corrections to achieve sub-millimetric accuracy.The company is currently planning to commence a limited market release in the first half of 2024, with a planned full market release in the second half of 2024.The latest regulatory approval is ...